Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ-252 in Non-Segmental Facial Vitiligo
NCT04811131Phase 2Terminated
- Sponsor
- Arcutis Biotherapeutics
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivarmacitinib in nonsegmental vitiligo (4 arms), sponsored by Arcutis Biotherapeutics. Primary endpoint: Percentage of Participants Achieving 75% Reduction in Facial Vitiligo Area Scoring Index at 24 weeks. Started Mar 2021; status: terminated.
02
Drugs
ivarmacitinib
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on NCT04811131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811131.